Drug Trial Radar · NCT05583526
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
607
Actual
Start
Dec 1, 2022
Primary completion
Feb 5, 2026
Study completion Feb 5, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Conditions
- Stable Nonsegmental Vitiligo
- Active Nonsegmental Vitiligo
Interventions
RitlecitinibDrug
50 mg capsule
PlaceboDrug
Matching capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52Time frame: Week 52
- Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52Time frame: Week 52
- Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalitiesTime frame: Baseline through Week 52
Locations
115 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham Faculty Office Towers (Regulatory
Birmingham, Alabama
California Dermatology & Clinical Research Institute
Encinitas, California
Marvel Clinical Research
Huntington Beach, California
Wallace Medical Group, Inc
Los Angeles, California
Audiology
Washington D.C., District of Columbia
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Center for Dermatology and Dermatologic Surgery
Washington D.C., District of Columbia
Encore Medical Research of Boynton Beach
Boynton Beach, Florida
Skin Care Research
Hollywood, Florida
Clever Medical Research
Miami, Florida
Ziaderm Research LLC
North Miami Beach, Florida
Olympian Clinical Research
St. Petersburg, Florida
ForCare Clinical Research
Tampa, Florida
Advanced Medical Research, PC.
Sandy Springs, Georgia
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Velocity Clinical Research at The Dermatology Clinic, Baton Rouge
Baton Rouge, Louisiana
DelRicht Research
Baton Rouge, Louisiana
The NeuroMedical Center (XRay)
Baton Rouge, Louisiana
DelRicht Research
New Orleans, Louisiana
Prairieville Family Hospital (XRay)
Prairieville, Louisiana
Visage Dermatology and Aesthetic Center
Bowie, Maryland
Lawrence J Green, MD LLC
Rockville, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Hamzavi Dermatology - Canton
Canton, Michigan
Skin Specialists, PC
Omaha, Nebraska
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
SUNY Downstate Health Sciences University
Brooklyn, New York
Icahn School of Medicine at Mount Sinai
New York, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Clinical & Translational Research Center (CTRC)
Chapel Hill, North Carolina
Accellacare - Wilmington
Wilmington, North Carolina
Accellacare
Wilmington, North Carolina
PMG Research of Wilmington, LLC
Wilmington, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Remington Davis Clinical Research
Columbus, Ohio
Remington-Davis, Inc
Columbus, Ohio
Medical University of South Carolina
Charleston, South Carolina
Bellaire Dermatology Associates
Bellaire, Texas
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.